Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib vs Trastuzumab in HER2-positive breast cancer
NCT01205217Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Dec 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of lapatinib in breast cancer, sponsored by GSK. Planned start Dec 2010; status: withdrawn.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01205217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01205217.